Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Title: Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial
Authors: Balduzzi, Adriana; Glogova, Evgenia; Peters, Christina; Sedlacek, Petr; Dalle, Jean-Hugues; Locatelli, Franco; Meisel, Roland; Burkhardt, Birgit; Buechner, Jochen; Wachowiak, Jacek; Bierings, Marc; Staciuk, Raquel; Graphakos, Stelios; Güngör, Tayfun; Yesilipek, Akif; Svec, Peter; Palma, Julia; Krivan, Gergely; Diaz-de-Heredia, Cristina; Limido, Francesca; Ansari, Marc; Kalwak, Krzysztof; Bader, Peter; Ifversen, Marianne
Contributors: Balduzzi, A; Glogova, E; Peters, C; Sedlacek, P; Dalle, J; Locatelli, F; Meisel, R; Burkhardt, B; Buechner, J; Wachowiak, J; Bierings, M; Staciuk, R; Graphakos, S; Güngör, T; Yesilipek, A; Svec, P; Palma, J; Krivan, G; Diaz-de-Heredia, C; Limido, F; Ansari, M; Kalwak, K; Bader, P; Ifversen, M
Publisher Information: Ferrata Storti Foundation; IT
Publication Year: 2026
Collection: Università degli Studi di Milano-Bicocca: BOA (Bicocca Open Archive)
Subject Terms: minimal residual disease; hematopoietic stem cell transplantation; childhood; acute lymphoblastic leukemia; FORUM Trial
Description: In the randomized cohort of the international phase-III FORUM trial, which showed the superiority of total-body irradiation (TBI) over chemotherapy-based conditioning prior to hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL), type of conditioning and remission phase, but not pre-HSCT minimal residual disease (MRD), were associated with outcome. We report the impact of MRD within the extended FORUM cohort. Patients (N=1,014) aged 4-21 years old, transplanted from a matched donor who had ≥1 MRD measurement prior to and/or 100 days and/or one year after HSCT were eligible. A threshold of 0.01% defined MRD positivity versus negativity. Prior to HSCT, 21% of patients were MRDpos. Three-year event-free survival (EFS) was 0.73 and 0.59 (P
Document Type: article in journal/newspaper
File Description: STAMPA
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/40820816; info:eu-repo/semantics/altIdentifier/wos/WOS:001660777000013; volume:111; issue:1 (January, 2026); firstpage:122; lastpage:134; numberofpages:13; journal:HAEMATOLOGICA; https://hdl.handle.net/10281/569005
DOI: 10.3324/haematol.2025.287456
Availability: https://hdl.handle.net/10281/569005; https://doi.org/10.3324/haematol.2025.287456
Rights: info:eu-repo/semantics/openAccess ; license:Creative Commons ; license uri:http://creativecommons.org/licenses/by-nc/4.0/
Accession Number: edsbas.9A354DE9
Database: BASE